Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03963206
Other study ID # 69HCL18_0977
Secondary ID 2019-001142-18
Status Completed
Phase Phase 4
First received
Last updated
Start date September 9, 2019
Est. completion date October 7, 2021

Study information

Verified date November 2021
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hepatocellular carcinoma (HCC) is a common tumor (the 8th leading cause of cancer in France) and has a poor prognosis. It is the 3rd leading cause of cancer deaths in the world. In the early stages (low tumor mass), HCC can be treated for curative purposes by surgical resection, percutaneous ablation or liver transplantation. When the tumor mass is larger (> 3 nodules) but remains confined to the liver, the standard treatment is hepatic intra-arterial chemoembolization (TACE). In the event of failure of the latter or if the tumor dissemination progresses in the portal venous system or in the form of metastases, the systemic treatments are then indicated. In 1st line, the reference treatment is a tyrosine kinase inhibitor (ITK) Sorafenib. Cabozantinib obtained the European and French authorization (AMM) in November 2018 for its use in case of failure of Sorafenib in patients with HCC. The main objective is the evaluation of the safety of Cabozantinib administered to patients with intermediate HCC ineligible for chemoembolization or advanced HCC after failure of Sorafenib and possibly another systemic anticancer line.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date October 7, 2021
Est. primary completion date October 7, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major patient (age = 18 years). - Patient with a histologically proven HCC, or by radiology if cirrhotic liver (according to international recommendations). Patient with stage B BCLC classification after failure or impossibility of transarterial chemoembolization (TACE), or advanced stage C having already received one to two systemic lines, including one by Sorafenib. - eastern cooperative oncology group score of 0 or 1 (ECOG). - Child-Pugh A5 or A6 score. - Disease evaluable by RECIST v1.1 and mRECIST. - Hemoglobin> 8.5g / dL. - Platelets> 60 giga / L. - neutrophils> 1.2 giga / L. - ALAT and ASAT <5N - Patient having a normal magnesium level - Clearance with creatinine> 40ml / min (by the MDRD formula). - For patients who have had radiotherapy on the liver: a wash out of at least one month before the start of the treatment under study must be respected. - For patients who have had a radioembolization a wash out of at least three months before the beginning of the treatment under study must be respected. - Patient who agreed to participate in the study and signed the informed consent. - Patient affiliated to a social security scheme. Exclusion Criteria: - Patient with another cancer not cured or whose complete remission has been obtained for less than 2 years compared to the date of inclusion in CLERANCE. - Patients eligible for surgical resection or radiofrequency ablation or liver transplantation or TACE according to international recommendations. - Patient who has already had more than two lines of systemic treatment for his HCC (tyrosine kinase inhibitor, intravenous cytotoxic chemotherapy, immunotherapy, hormonal therapy for HCC). - Patient who has never received Sorafenib in his previous systemic line (s). - Patient who has already received a c-MET inhibitor. - Patient with chronic viral B infection known not treated with a nucleoside / nucleotide analogue. - Patients infected with HIV known (even if it is viro-suppressed by anti-retroviral treatments). - Patients with or at risk for severe bleeding (a gastroscopy should be performed every two years if the patient doesn't have varicose veins and every year if the patient has varicose vein). - Patients with inflammatory bowel diseases (Crohn's disease, ulcerative colitis, peritonitis, diverticulitis, appendicitis) - Patient with galactose intolerance or Lapp lactase deficiency, or glucose or galactose malabsorption syndrome. - Patients with tumor infiltration of the digestive tract with risk of fistulation - Patients with recent digestive surgery (<1 month) or not yet fully healed. - Patients with QTcF> 480 ms on inclusion ECG. - Known hypersensitivity to Cabozantinib or to any of the excipients. - Pregnant or nursing woman. - Patient of childbearing age without mechanical contraception. - Patient placed under safeguard of justice (tutelage or curatorship). - Patient not benefiting from social security. - Patient participating in another interventional research in progress or including an exclusion period still in progress at pre-inclusion (except interventional research with minimal risks and constraints that do not interfere with the judgment criteria of the study according to the judgment of the coordinating investigator). Chronic active C infection is not a contraindication. Treatment with direct antiviral agents is left to the discretion of each investigator, but the viremic or cured status of each patient should be mentioned.

Study Design


Intervention

Drug:
Cabozantinib group
The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.

Locations

Country Name City State
France CHU Amiens Picardie - Hôpital Sud Amiens
France CHU Jean Minjoz Besançon
France Hôpital Avicenne Bobigny
France Centre Hospitalier de Boulogne sur mer Boulogne-sur-Mer
France Centre hospitalier universitaire Côte de nacre Caen
France Hôpital Beaujon Clichy
France CHRU de Lille-Hôpital Claude Huriez Lille
France CHU Dupuytren Limoges
France Hospices Civils de Lyon - Hôpital de la Croix Rousse Lyon
France APHM - Timone Marseille
France Centre Hospitalier Universitaire de Montpellier Montpellier
France APHP - Hôpital St Antoine Paris
France Hôpital haut- lévêque Pessac
France Hôpital Robert Debré - CHU de Reims Reims
France CHRU Rennes site pontchaillou Rennes
France CHU de St Etienne Saint Priest en Jarez
France CHU Toulouse PURPAN Toulouse
France Hôpital Brabois adulte - CHU de Nancy Vandoeuvre-les-Nancy

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary survival of the patient after start of treatment Overall Survival (OS) defined as the time (in months) between the start of treatment with Cabozantinib and the date of death from all causes; patients who are alive or lost to follow-up at the time of the analysis will be censored on the last follow-up date Year 1
Secondary dosage modification for adverse effect Incidence of changes in the dose of Cabozantinib for adverse effect during treatment (including daily dose reductions, dose spacings, discontinuation and permanent cessation of treatment for intolerance). Year 1
Secondary Daily median dose of Cabozantinib Daily median dose of Cabozantinib calculated between the start of treatment with Cabozantinib and the day of final cessation (including death) Year 1
Secondary Number of patients with each dose of Cabozantinib calculation of the number of patients with a dose of Cabozantinib 60 mg, 40 mg or 20 mg at the end of treatment or at the end of the study. Year1
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2
Recruiting NCT05537402 - LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC Phase 2